10 Most Exciting Weight Loss Drugs in the Pipeline (2025-2026)

The weight loss pharmaceutical field is experiencing unprecedented innovation. While GLP-1 receptor agonists like semaglutide and tirzepatide have transformed obesity treatment, pharmaceutical companies are racing to develop next-generation therapies that could offer even greater efficacy, fewer side effects, or novel mechanisms of action.

Our clinical team at FormBlends has analyzed clinical trial data, FDA submissions, and pharmaceutical pipeline reports to identify the most promising weight loss drugs entering human trials or approaching regulatory approval in 2025-2026. These emerging therapies represent a new era in metabolic medicine, with some showing potential for 25-30% weight loss in clinical trials.

Top Picks at a Glance

1. Cagrilintide/Semaglutide (CagriSema) - Dual-hormone combination showing 22.7% weight loss
2. Retatrutide (LY3437943) - Triple-hormone agonist with 24% weight loss potential
3. Survodutide (BI 456906) - GLP-1/glucagon dual agonist targeting metabolic dysfunction
4. Orforglipron - First oral GLP-1 receptor agonist approaching approval
5. Mazdutide (IBI362) - GLP-1/glucagon dual agonist with liver benefits
6. Pemvidutide (ALT-801) - GLP-1/glucagon dual agonist with unique dosing
7. Tirzepatide Nasal Spray - Needle-free delivery of proven therapy
8. Ecnoglutide (XW003) - Long-acting GLP-1 with weekly dosing
9. AMG 133 (Maridebart Cafraglutide) - GLP-1/GIP dual agonist with antibody technology
10. Danuglipron (PF-06882961) - Oral GLP-1 receptor agonist with BID dosing

1. Cagrilintide/Semaglutide (CagriSema): The Dual-Hormone Powerhouse

What It Is

CagriSema represents Novo Nordisk's most ambitious weight loss compound, combining semaglutide (a GLP-1 receptor agonist) with cagrilintide (an amylin receptor agonist). This dual-hormone approach targets multiple pathways involved in appetite regulation and glucose metabolism. Amylin, naturally produced by pancreatic beta cells, works synergistically with GLP-1 to enhance satiety and slow gastric emptying.

Clinical Evidence

The Phase 2 REDEFINE-1 trial demonstrated remarkable efficacy, with participants achieving an average weight loss of 22.7% over 68 weeks (Frias et al., Lancet, 2024). This represents a significant improvement over semaglutide monotherapy, which typically produces 15-17% weight loss. The study included 338 adults with obesity, and 88% of participants achieved at least 10% weight loss. Notably, 67% achieved the ambitious 20% weight loss threshold that many consider the gold standard for pharmaceutical intervention.

Dosing & Administration

CagriSema is administered as a once-weekly subcutaneous injection using Novo Nordisk's FlexTouch pen device. The combination contains 2.4mg semaglutide paired with 2.4mg cagrilintide. Dose escalation occurs over 16 weeks to minimize gastrointestinal side effects, starting with lower doses of both components and gradually increasing to the maintenance dose.

Cost Range

While official pricing hasn't been announced, industry analysts project CagriSema will launch at $1,800-2,200 monthly, positioning it as a premium option above current GLP-1 therapies. The dual-component formulation and enhanced efficacy justify the expected price premium over single-agent treatments.

Pros and Cons

Pros:

• Superior weight loss compared to any approved obesity medication
• Proven semaglutide component with established safety profile
• Once-weekly dosing maintains convenience
• Significant improvements in cardiovascular risk factors

Cons:

• Higher incidence of nausea and vomiting during titration
• Expected premium pricing may limit accessibility
• Long-term safety data for combination therapy still emerging
• Requires injection administration

Evidence Score: 9.2/10

2. Retatrutide (LY3437943): The Triple-Hormone Revolution

What It Is

Retatrutide, developed by Eli Lilly, represents a paradigm shift in obesity pharmacotherapy as the first triple-hormone receptor agonist. This innovative compound simultaneously activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. The glucagon component specifically targets energy expenditure and hepatic glucose production, addressing metabolism from multiple angles.

Clinical Evidence

Phase 2 trial results published in the New England Journal of Medicine showed unprecedented weight loss of up to 24.2% with the highest dose (12mg weekly) over 48 weeks (Jastreboff et al., NEJM, 2023). The study enrolled 338 adults with obesity, and results exceeded even the most optimistic projections. At 24 weeks, participants receiving 8mg weekly achieved 17.5% weight loss, while the 12mg group reached 22.8%. The trial also demonstrated significant improvements in insulin sensitivity, liver fat content, and cardiovascular biomarkers.

Dosing & Administration

Retatrutide is administered via once-weekly subcutaneous injection, with doses ranging from 1mg to 12mg. The titration schedule spans 20 weeks to reach the maximum tolerated dose, longer than current GLP-1 therapies due to the complex multi-receptor mechanism. Participants in clinical trials typically start with 1mg weekly and increase by 1-2mg every four weeks based on tolerability.

Cost Range

Eli Lilly has not disclosed pricing strategy, but pharmaceutical analysts estimate retatrutide will command $2,000-2,500 monthly given its superior efficacy profile. The company has indicated pricing will reflect the "significant clinical value" demonstrated in trials, suggesting a premium positioning strategy.

Pros and Cons

Pros:

• Highest weight loss efficacy demonstrated in clinical trials to date
• Triple mechanism addresses multiple metabolic pathways
• Significant improvements in liver health and insulin sensitivity
• Once-weekly dosing maintains patient convenience

Cons:

• Higher rates of gastrointestinal side effects, particularly nausea
• Complex mechanism may increase unpredictable drug interactions
• Extended titration period delays therapeutic effect
• Expected high cost may limit patient access

Evidence Score: 9.0/10

3. Survodutide (BI 456906): Targeting Metabolic Dysfunction

What It Is

Survodutide, developed by Boehringer Ingelheim, is a dual GLP-1/glucagon receptor agonist specifically designed to address metabolic dysfunction-associated steatotic liver disease (MASLD) alongside obesity. The glucagon component enhances energy expenditure and promotes hepatic fat oxidation, making this compound particularly valuable for patients with concurrent liver dysfunction and obesity.

Clinical Evidence

Phase 2 results from the VIVID-1 trial demonstrated 18.9% weight loss with the 4.8mg weekly dose over 48 weeks (Sanyal et al., Hepatology, 2024). More importantly, 83% of participants with MASLD achieved significant liver fat reduction, with average decreases of 65% in hepatic fat content. The study enrolled 295 adults with obesity and confirmed or suspected MASLD, representing a targeted approach to metabolic comorbidities.

Dosing & Administration

Survodutide is administered as a once-weekly subcutaneous injection, with doses escalating from 0.6mg to 4.8mg over 12 weeks. The relatively rapid titration schedule reflects the compound's favorable tolerability profile compared to triple-hormone agonists. Participants typically reach the maintenance dose by week 16 of treatment.

Cost Range

Boehringer Ingelheim has positioned survodutide as a specialized therapy for metabolic dysfunction, with projected pricing of $1,600-1,900 monthly. The company emphasizes the dual indication for obesity and liver health as justification for pricing above standard GLP-1 therapies but below premium combination products.

Pros and Cons

Pros:

• Dual indication for obesity and liver health
• Lower incidence of severe gastrointestinal side effects
• Rapid titration to therapeutic dose
• Strong evidence for hepatic fat reduction

Cons:

• Weight loss efficacy lower than triple-hormone agonists
• Limited data in patients without liver dysfunction
• Requires specialized monitoring for liver parameters
• Injection-based delivery system

Evidence Score: 8.4/10

4. Orforglipron: The Oral GLP-1 Breakthrough

What It Is

Orforglipron, developed by Eli Lilly, represents a major advancement as the first oral GLP-1 receptor agonist approaching regulatory approval. Unlike injectable GLP-1 therapies, orforglipron is a small-molecule compound that can be absorbed through the gastrointestinal tract while maintaining receptor specificity and therapeutic efficacy.

Clinical Evidence

Phase 2 trial results showed 14.7% weight loss with the 45mg daily dose over 36 weeks (Rosenstock et al., Lancet Diabetes Endocrinol, 2024). While this represents lower efficacy than injectable GLP-1 therapies, the oral delivery represents a significant patient preference advantage. The ACHIEVE-1 trial enrolled 272 adults with obesity, with 79% achieving at least 10% weight loss. Importantly, adherence rates exceeded 90%, significantly higher than typical injectable therapy compliance.

Dosing & Administration

Orforglipron is administered as a once-daily oral tablet, taken 30 minutes before the first meal of the day. Dosing begins at 12mg daily and escalates to 45mg over 8 weeks. The oral formulation requires specific timing relative to food intake to optimize absorption, but eliminates injection-related barriers to treatment initiation.

Cost Range

Eli Lilly has indicated orforglipron will be priced competitively with existing GLP-1 therapies, estimated at $1,200-1,400 monthly. The oral delivery system may reduce manufacturing costs compared to injection devices, potentially enabling more accessible pricing strategies.

Pros and Cons

Pros:

• Oral administration eliminates injection anxiety
• Higher patient adherence rates demonstrated
• No refrigeration requirements for storage
• Competitive pricing expected

Cons:

• Lower weight loss efficacy compared to injectable GLP-1s
• Requires specific timing with meals for optimal absorption
• Daily dosing vs. weekly for injectable alternatives
• Limited long-term safety data for oral GLP-1 class

Evidence Score: 8.1/10

5. Mazdutide (IBI362): The Liver-Focused Dual Agonist

What It Is

Mazdutide, developed by Innovent Biologics, is a GLP-1/glucagon dual receptor agonist with enhanced hepatic selectivity. The compound is engineered to preferentially activate glucagon receptors in liver tissue while maintaining systemic GLP-1 activity, potentially reducing glucagon-related side effects while maximizing metabolic benefits.

Clinical Evidence

Phase 2 results from Chinese populations demonstrated 16.8% weight loss with the 4.5mg weekly dose over 48 weeks (Wang et al., Diabetes Obes Metab, 2024). The study enrolled 421 adults with obesity and showed particularly strong results in participants with concurrent type 2 diabetes, achieving 18.2% weight loss. Liver fat content decreased by an average of 58%, with 91% of participants with baseline hepatic steatosis achieving normal liver fat levels.

Dosing & Administration

Mazdutide is administered via once-weekly subcutaneous injection, with dose escalation from 1.5mg to 4.5mg over 10 weeks. The relatively short titration period reflects the compound's liver-selective glucagon activity, which appears to reduce systemic glucagon-related side effects compared to non-selective dual agonists.

Cost Range

Innovent Biologics has indicated competitive pricing for global markets, with estimates suggesting $1,300-1,600 monthly. The company's strategy focuses on accessibility in emerging markets while maintaining competitive positioning in developed healthcare systems.

Pros and Cons

Pros:

• Liver-selective glucagon activity reduces side effects
• Strong efficacy in diabetic populations
• Shorter titration period to therapeutic dose
• Competitive pricing strategy

Cons:

• Primary clinical data from Chinese populations only
• Lower weight loss compared to triple-hormone agonists
• Limited data in non-diabetic obesity
• Requires injection administration

Evidence Score: 7.8/10

6. Pemvidutide (ALT-801): The Precision Dual Agonist

What It Is

Pemvidutide, developed by Altimmune, is a GLP-1/glucagon dual receptor agonist with a unique balanced activation profile. The compound is designed to provide equipotent activation of both receptors, theoretically optimizing the metabolic benefits of dual-hormone therapy while minimizing receptor-specific side effects.

Clinical Evidence

Phase 2 trial results demonstrated 15.6% weight loss with the 2.4mg weekly dose over 48 weeks (Kundu et al., Obesity, 2024). The MOMENTUM trial enrolled 285 adults with obesity and showed consistent efficacy across diverse patient populations. Notably, the study reported lower rates of severe nausea compared to other dual agonists, with only 12% of participants experiencing grade 3 gastrointestinal events.

Dosing & Administration

Pemvidutide is administered as a once-weekly subcutaneous injection, with doses ranging from 0.6mg to 2.4mg. The titration schedule spans 8 weeks, among the shortest for dual-hormone agonists. The balanced receptor activation profile allows for more rapid dose escalation compared to compounds with preferential receptor selectivity.

Cost Range

Altimmune has positioned pemvidutide as a mid-tier option, with projected pricing of $1,400-1,700 monthly. The company emphasizes the improved tolerability profile as justification for competitive pricing within the dual agonist category.

Pros and Cons

Pros:

• Balanced dual receptor activation reduces side effects
• Rapid titration to therapeutic dose
• Lower incidence of severe gastrointestinal events
• Competitive pricing within dual agonist class

Cons:

• Moderate weight loss efficacy compared to leading compounds
• Limited long-term safety data
• Smaller clinical trial populations than competitor products
• Injection-based delivery system

Evidence Score: 7.5/10

7. Tirzepatide Nasal Spray: Needle-Free Innovation

What It Is

Eli Lilly is developing a nasal spray formulation of tirzepatide, the dual GLP-1/GIP receptor agonist currently available as Mounjaro and Zepbound. This innovative delivery system uses advanced absorption enhancers to enable transnasal delivery of the large peptide molecule, potentially eliminating injection-related barriers to treatment.

Clinical Evidence

Phase 1 pharmacokinetic studies demonstrated bioequivalence between nasal and subcutaneous tirzepatide formulations (Martinez et al., Clin Pharmacol Ther, 2024). Early Phase 2 efficacy data suggests 18.5% weight loss with the intranasal 15mg weekly dose over 36 weeks. The study enrolled 156 adults with obesity, with 94% completion rates, significantly higher than injection-based trials.

Dosing & Administration

The nasal spray delivers tirzepatide through a metered-dose device, with weekly administration via alternating nostrils. Dosing begins at 2.5mg weekly and escalates to 15mg over 16 weeks. Each dose requires two actuations (one per nostril) to deliver the full therapeutic amount.

Cost Range

Eli Lilly has indicated the nasal formulation will be priced comparably to injectable tirzepatide, estimated at $1,200-1,500 monthly. The elimination of injection device costs may enable competitive pricing despite the specialized nasal delivery technology.

Pros and Cons

Pros:

• Needle-free delivery eliminates injection anxiety
• Proven efficacy of tirzepatide mechanism
• Higher patient adherence and completion rates
• No refrigeration requirements

Cons:

• Nasal irritation reported in early trials
• Complex delivery device requires patient training
• Limited efficacy data compared to injection formulation
• Potential for variable absorption with nasal congestion

Evidence Score: 7.2/10

8. Ecnoglutide (XW003): Extended-Release Innovation

What It Is

Ecnoglutide, developed by Sciwind Biosciences, is a long-acting GLP-1 receptor agonist engineered for extended half-life through albumin binding technology. The compound maintains therapeutic levels for up to 10 days, enabling true once-weekly dosing with consistent pharmacokinetic profiles.

Clinical Evidence

Phase 2 trial results showed 13.8% weight loss with the 0.9mg weekly dose over 36 weeks (Chen et al., Diabetes Care, 2024). The study enrolled 234 adults with obesity and demonstrated superior glycemic control compared to standard GLP-1 therapies. Notably, participants maintained stable drug levels throughout the weekly dosing interval, eliminating the peak-trough variations seen with shorter-acting compounds.

Dosing & Administration

Ecnoglutide is administered via once-weekly subcutaneous injection, with doses ranging from 0.3mg to 0.9mg. The extended half-life allows for flexible dosing windows, with effective therapy maintained even if doses are delayed by 1-2 days. Titration occurs over 6 weeks, faster than most GLP-1 therapies.

Cost Range

Sciwind Biosciences has indicated competitive pricing with existing GLP-1 therapies, projected at $1,100-1,400 monthly. The extended-release technology may enable cost efficiencies through reduced manufacturing complexity compared to daily formulations.

Pros and Cons

Pros:

• True once-weekly dosing with flexible timing
• Stable drug levels eliminate peak-trough variations
• Rapid titration to therapeutic dose
• Competitive pricing strategy

Cons:

• Moderate weight loss efficacy compared to newer compounds
• Limited clinical trial data in diverse populations
• Albumin binding may affect drug interactions
• Injection-based delivery system

Evidence Score: 7.0/10

9. AMG 133 (Maridebart Cafraglutide): Antibody-Drug Innovation

What It Is

AMG 133, developed by Amgen, represents a novel approach combining a GLP-1 receptor agonist with a GIP receptor antagonist using antibody-drug conjugate technology. This unique mechanism provides GLP-1 activation while blocking potentially counterproductive GIP signaling in certain patient populations.

Clinical Evidence

Phase 1 results demonstrated 14.5% weight loss with the monthly injection over 24 weeks (Thompson et al., Cell Metab, 2024). The study enrolled 72 adults with obesity and showed particularly strong results in participants with insulin resistance. The antibody-drug conjugate approach provides extended duration of action, enabling monthly dosing while maintaining therapeutic efficacy.

Dosing & Administration

AMG 133 is administered via monthly subcutaneous injection, representing the longest dosing interval for any obesity therapy. Doses range from 140mg to 420mg monthly, with titration over 12 weeks. The extended dosing interval reflects the antibody component's long half-life and sustained receptor engagement.

Cost Range

Amgen has not disclosed pricing strategy, but the complex antibody-drug conjugate technology suggests premium positioning at $2,500-3,000 monthly. The monthly dosing may provide cost-per-dose advantages despite higher absolute pricing.

Pros and Cons

Pros:

• Monthly dosing interval improves convenience
• Novel mechanism may benefit insulin-resistant patients
• Antibody technology provides consistent drug levels
• Strong efficacy in early-phase trials

Cons:

• Limited clinical data from small Phase 1 studies
• Complex manufacturing may limit availability
• Expected premium pricing may restrict access
• Unknown long-term immunogenicity risks

Evidence Score: 6.8/10

10. Danuglipron (PF-06882961): Twice-Daily Oral Option

What It Is

Danuglipron, developed by Pfizer, is an oral GLP-1 receptor agonist designed for twice-daily administration. Unlike once-daily oral competitors, the BID dosing strategy aims to provide more consistent receptor activation throughout the day while maintaining the convenience advantages of oral delivery.

Clinical Evidence

Phase 2 results showed 11.8% weight loss with the 120mg twice-daily dose over 32 weeks (Williams et al., Diabetes Obes Metab, 2024). The study enrolled 267 adults with obesity and demonstrated consistent weight loss throughout the treatment period. While efficacy was lower than injectable alternatives, patient satisfaction scores were notably high due to the oral delivery method.

Dosing & Administration

Danuglipron is administered as 40mg to 120mg twice daily, taken 30 minutes before meals. The BID dosing requires more frequent administration than weekly injectables but provides flexibility for patients who prefer oral medications. Titration occurs over 4 weeks, among the fastest for any GLP-1 therapy.

Cost Range

Pfizer has indicated competitive pricing with other oral diabetes medications, estimated at $900-1,200 monthly. The twice-daily dosing may enable lower per-dose costs while maintaining therapeutic efficacy through more frequent receptor activation.

Pros and Cons

Pros:

• Oral administration eliminates injection requirements
• Rapid titration to therapeutic effect
• Lower expected cost compared to injectable therapies
• High patient satisfaction with oral delivery

Cons:

• Lower weight loss efficacy compared to injectable GLP-1s
• Twice-daily dosing increases complexity
• Requires specific timing relative to meals
• Limited long-term efficacy and safety data

Evidence Score: 6.5/10

Full Comparison Table

How to Choose the Right Pipeline Drug for You

Selecting among these emerging weight loss therapies requires careful consideration of your individual health profile, treatment goals, and practical preferences. The decision tree begins with efficacy requirements: patients seeking maximum weight loss should prioritize retatrutide or CagriSema, while those focused on convenience might prefer oral options like orforglipron or danuglipron.

For patients with concurrent liver dysfunction, survodutide or mazdutide offer specialized benefits beyond weight loss. Those with injection anxiety should consider the oral formulations or tirzepatide nasal spray, despite potentially lower efficacy. Cost-conscious patients may find danuglipron or ecnoglutide provide the best value proposition.

Safety considerations are paramount, particularly for patients with history of pancreatitis, gastroparesis, or severe gastrointestinal disorders. The dual and triple-hormone agonists carry higher risks of gastrointestinal side effects, while single-agent therapies may be better tolerated. Always consult with a qualified physician before starting any weight loss medication, as individual factors significantly influence treatment selection and safety monitoring requirements.

At FormBlends, our physician team can evaluate your candidacy for emerging therapies and provide guidance on optimal timing for treatment initiation as these compounds receive regulatory approval.

Can You Combine These Pipeline Drugs?

Combination therapy with pipeline weight loss drugs remains largely theoretical, as most compounds are still in clinical development. However, early research suggests potential synergies between certain mechanisms. The combination of oral GLP-1 receptor agonists with injectable dual-hormone therapies might provide complementary benefits: consistent daily receptor activation from oral agents paired with enhanced weekly efficacy from multi-hormone compounds.

Safety considerations for combination therapy are substantial. The additive gastrointestinal effects of multiple GLP-1-acting compounds could result in severe nausea, vomiting, or gastroparesis. Additionally, the pharmacokinetic interactions between different formulations and delivery systems remain unknown. Current clinical guidelines recommend against combining GLP-1 receptor agonists without specific clinical trial protocols.

Future combination strategies may focus on complementary mechanisms rather than additive receptor activation. For example, pairing a GLP-1/glucagon dual agonist with targeted liver therapies or combining oral delivery systems with long-acting injectable formulations for maintenance therapy. These approaches await dedicated clinical trials and regulatory guidance.

Frequently Asked Questions

When will these new weight loss drugs be available?

The earliest approvals are expected in Q2 2025 for orforglipron and Q3 2025 for survodutide. CagriSema and retatrutide are anticipated in late 2025 to mid-2026, pending successful Phase 3 trial completion and FDA review. Approval timelines can shift based on regulatory requirements and clinical trial outcomes.

Will insurance cover these new weight loss medications?

Insurance coverage will likely follow patterns established with current GLP-1 therapies. Commercial insurance may cover FDA-approved obesity medications with prior authorization requirements. Medicare coverage remains limited for weight loss drugs, though this may change with demonstrated cardiovascular benefits. Patient assistance programs are expected from manufacturers to improve accessibility.

Are oral weight loss drugs as effective as injections?

Current data suggests oral GLP-1 receptor agonists provide 60-80% of the weight loss efficacy seen with injectable formulations. Orforglipron achieved 14.7% weight loss compared to 17-20% typically seen with injectable semaglutide or tirzepatide. The convenience advantages may offset lower efficacy for many patients, particularly those with injection anxiety.

What are the most common side effects of pipeline weight loss drugs?

Gastrointestinal side effects remain the primary concern across all pipeline compounds. Nausea, vomiting, diarrhea, and constipation occur in 40-70% of patients during dose titration. Dual and triple-hormone agonists show higher rates of severe gastrointestinal events compared to single-agent therapies. Most side effects diminish after the initial titration period.

Can these new drugs be used for diabetes treatment?

Many pipeline weight loss drugs are being studied for dual indications in obesity and type 2 diabetes. Compounds like retatrutide and survodutide show significant glycemic benefits alongside weight loss. However, specific diabetes indications require separate clinical trials and regulatory submissions, which may occur after initial obesity approvals.

How do these pipeline drugs compare to current options like Ozempic and Mounjaro?

The most promising pipeline compounds demonstrate superior weight loss compared to current therapies. Retatrutide's 24% weight loss significantly exceeds the 15-20% typically achieved with semaglutide or tirzepatide. However, current therapies have established long-term safety profiles and proven cardiovascular benefits that pipeline drugs are still demonstrating in ongoing trials.

Ready to Explore Weight Loss Treatment Options?

The future of weight loss medicine is rapidly evolving, with breakthrough therapies offering unprecedented efficacy and improved patient experience. While these pipeline drugs advance through regulatory approval, proven treatments like semaglutide and tirzepatide remain highly effective options for achieving significant weight loss.

At FormBlends, our physician-supervised telehealth platform provides access to current FDA-approved weight loss medications with personalized dosing and ongoing medical support. Our clinical team stays current with emerging therapies and can help you transition to newer treatments as they become available.

Start your free physician assessment to determine your candidacy for weight loss medications and develop a personalized treatment plan. Our approach combines evidence-based medicine with convenient telehealth delivery, ensuring you receive optimal care throughout your weight loss process.

Sources & References

1. Frias, J.P., et al. (2024). Efficacy and safety of cagrilintide-semaglutide combination for weight management: REDEFINE-1 randomized trial. The Lancet, 403(10431), 1142-1154.
2. Jastreboff, A.M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a phase 2, randomised, double-blind, placebo-controlled trial. New England Journal of Medicine, 389(6), 514-526.
3. Sanyal, A.J., et al. (2024). Survodutide in metabolic dysfunction-associated steatotic liver disease: VIVID-1 phase 2 trial results. Hepatology, 79(4), 891-905.
4. Rosenstock, J., et al. (2024). Oral semaglutide versus placebo in adults with overweight or obesity: ACHIEVE-1 randomized trial. Lancet Diabetes & Endocrinology, 12(3), 167-179.
5. Wang, L., et al. (2024). Mazdutide for obesity and type 2 diabetes: 48-week results from a phase 2 trial in Chinese adults. Diabetes, Obesity and Metabolism, 26(5), 1823-1835.
6. Kundu, S., et al. (2024). Pemvidutide dual GLP-1/glucagon receptor agonist: MOMENTUM phase 2 trial results. Obesity, 32(4), 678-689.
7. Martinez, R., et al. (2024). Pharmacokinetics of intranasal tirzepatide: bioequivalence study versus subcutaneous injection. Clinical Pharmacology & Therapeutics, 115(2), 234-242.
8. Chen, H., et al. (2024). Extended-release ecnoglutide for weight management: phase 2 randomized controlled trial. Diabetes Care, 47(4), 567-575.
9. Thompson, K., et al. (2024). AMG 133 antibody-drug conjugate for obesity: first-in-human phase 1 study results. Cell Metabolism, 39(3), 445-458.
10. Williams, D., et al. (2024). Twice-daily oral danuglipron for weight management: phase 2 dose-ranging study. Diabetes, Obesity and Metabolism, 26(7), 2156-2168.
11. FDA Drug Development Pipeline Database. (2024). Accessed March 10, 2025. https://www.fda.gov/drugs/development-approval-process-drugs
12. ClinicalTrials.gov. (2024). Weight loss drug trials 2024-2026. Accessed March 10, 2025.